Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A pediatric oncology group phase III trial

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 246-254

  Mahoney Jr , Donald H ^a   Shuster, Jonathan ^a   Nitschke, Ruprecht ^a   Lauer, Stephen J ^a   Winick, Naomi ^a   Steuber, C Philip ^a   Camitta, Bruce ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER RECURRENCE; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STOMATITIS; THROMBOCYTOPENIA;

EID: 0344333442     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.246     Document Type: Article

References (53)

1. Pui C-H: Childhood leukemias. N Engl J Med 332:1618-1630, 1995
2. Reiter A, Schrappe M, Wolf-Dieter L, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
3. Schorin MA, Blattner S, Gelber RD, et al: Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital acute lymphoblastic leukemia consortium protocol 85-01. J Clin Oncol 12:740-747, 1994
4. Rivera GK, Raimondi SC, Hancock ML, et al: Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 337:61-66, 1991
5. Veerman AJP, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high risk childhood acute lymphoblastic leukemia: Results of protocol ALL-VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
6. Land VJ, Shuster JJ, Crist WM, et al: Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation therapy for childhood B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1939-1945, 1994
7. Camitta B, Mahoney D, Leventhal B, et al: Intensive intravenous methotrexate and mercaptopurine treatment of higher risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 12:1383-1389, 1994
8. Ackland SP, Schilsky RL: High dose methotrexate: A critical reappraisal. J Clin Oncol 5:2017-2031, 1987
9. Abromowitch M, Ochs J, Pui C-H, et al: Efficacy of high dose methotrexate in childhood acute lymphocytic leukemia: Analysis by contemporary risk classifications. Blood 71:866-869, 1988
10. Pui C-H, Simone JV, Hancock ML, et al: Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: Long-term results of St. Jude total therapy study X. Leukemia 6:150-157, 1992
11. Winick N, Bowman WP, Arencibia-Mireles O, et al: Prolonged intensive oral methotrexate does not induce its own malabsorption. Cancer Ther Control 1:245-250, 1990
12. Winick N, Freidman H, Bigner D, et al: Methotrexate schedule dependent drug accumulation. Proc Am Assoc Cancer Res 29:A1146, 1988 (abstr)
13. Winick N, Shuster JJ, Bowman WP, et al: Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 14:2803-2811, 1996
14. Bokkerink JA, Damen FJM, Hulscher MW, et al: Biochemical evidence of synergistic combination treatment with methotrexate and 6-mercaptopurine in acute lymphoblastic leukemia. Hematol Bluttransfus 3:110-117, 1990
15. Pinkel D: Intravenous mercaptopurine: Life begins at 40. J Clin Oncol 11:1826-1831, 1993
16. Lafolie P, Hayder S, Bjork O, et al: Large inter-individual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non Hodgkin's lymphoma. Acta Paediatr Scand 75:797-803, 1986
17. Dibenedetto SP, Guardabasso V, Ragusa R, et al: 6-mercaptopurine cumulative dose: A critical factor of maintenace therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 11:252-258, 1994
18. Zimm S, Ettinger LJ, Holcenberger JC, et al: Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 45:1869-1873, 1985
19. Bostrom B, Erdmann G: Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 15:80-86, 1993
20. Camitta B, Leventhal B, Lauer S, et al: Intermediate dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study. J Clin Oncol 7:1539-1544, 1989
21. Mahoney DH, Camitta B, Leventhal BG, et al: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. Cancer 75:2623-2631, 1995
22. Pullen DJ, Crist WM, Falletta JM, et al: A Pediatric Oncology Group classification protocol for acute lymphocytic leukemia (ALinC 13): Immunologic phenotypes and correlation with treatment results, in Murphy SB, Gilbert JR (eds): Leukemia Research: Advances in Cell Biology and Treatment. Amsterdam, the Netherlands, Elsevier, 1949, pp 221-239
23. Look AT, Roberson PK, Williams DL, et al: Prognostic importance of blast cell DNA content in childhood acute lymphocytic leukemia. Blood 65:1079-1086, 1985
24. Pullen DJ, Crist WM, Falletta JM, et al: Southwest Oncology Group experience with immunological phenotyping in acute lymphocytic leukemia of childhood Cancer Res 41:4802-4809, 1981
25. Trueworthy R, Shuster J, Look T, et al: Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-precursor cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 10:606-613, 1992
26. Crist WM, Carroll A, Shuster JJ, et al: Poor prognosis of children with pre-B acute lymphoblastic leukemia with the t(1;19)(q23;p13): A Pediatric Oncology Group study. Blood 76:117-122, 1990
27. Fletcher JA, Lynch EA, Kimball VM, et al: Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood 77:435-439, 1991
28. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 35:1-39, 1977
29. Shuster JJ: Handbook of Sample Size Guidelines for Clinical Trials. Boca Raton, FL, CRC, 1990
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
31. Cox DR: Regression models and life-table (with discussion). J R Stat Soc B 34:187-220, 1972
32. Mahoney DH, Nitschke R, Lauer S, et al: Neurotoxicity (NT) in children with acute lymphoblastic leukemia (ALL) receiving intensive methotrexate schedules. A Pediatric Oncology Group Study. Proc Am Soc Clin Oncol 15:366, 1996 (abstr 1082)
33. Niemeyer CM, Gelber RD, Tarbel NJ, et al: Low dose versus high dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (protocol 81-01 update). Blood 78:2514-2519, 1991
34. Kamen BA, Winick NJ: High dose methotrexate therapy: Insecure rationale? Biochem Pharmacol 37:2713-2715, 1988
35. Kamen BA, Capdevilla A: Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci USA 83:5983-5987, 1986
36. Keefe DA, Capizzi RL, Rudnick SA: Methotrexate cytotoxicity for L5178 Y/ASN-lymphoblasts: Relationship of dose and duration of exposure to tumor cell viability. Cancer Res 42:1641-1645, 1982
37. Pullen J, Boyett J, Shuster J, et al: Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good risk and poor risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study. J Clin Oncol 11:839-849, 1993
38. Harris MB, Shuster JJ, Carroll A, et al: Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell cute lymphoblastic leukemia with a very low risk of treatment failure: A Pediatric Oncology Group study. Blood 79:3316-3324, 1992
39. Smith M, Arthur D, Camitta B, et al: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 14:18-24, 1996
40. Evans WE, Crom WR, Abromowitch M, et al: Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471-477, 1986
41. Evans WE, Schell MJ, Pui C-H: MTX clearnace is more important for intermediate risk ALL. J Clin Oncol 8:1115-1119, 1990
42. Whitehead VM, Rosenblatt DS, Vuchich MJ, et al: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76:44-49, 1990
43. Whitehead VM, Vuchick MJ, Lauer SJ, et al: Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>50 chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 80:1316-1323, 1992
44. Synold TW, Relling MV, Boyett JM, et al: Blast cell methotrexate polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996-2001, 1994
45. Hammond D, Sather H, Nesbit M, et al: Analysis of prognostic factors in acute lymphoblastic leukemia. Med Pediatr Oncol 14:124-134, 1986
46. Littman P, Coccia P, Bleyer WA, et al: Central nervous system prophylaxis in children with low risk acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 13:1443-1449, 1987
47. Conter V, Arico M, Valsecchi MG, et al: Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Munster based intensive chemotherapy. J Clin Oncol 13:2497-2502, 1995
48. Tubergen DG, Gilchrist GS, O'Brian RT, et al: Prevention of CNS relapse in intermediate risk acute lymphoblastic leukemia. Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group report. J Clin Oncol 11:520-526, 1993
49. Pinkel D, Woo S: Prevention and treatment of meningeal leukemia in children. Blood 84:355-366, 1994
50. Bertino JR: Leucovorin rescue revisited. J Clin Oncol 8:193-195, 1990
51. Borsi JD, Wesenberg F, Stokland T, Moe PJ: How much is too much? Folinic acid rescue in children with acute lymphoblastic leukaemia. Eur J Cancer 27:1006-1009, 1991
52. Kamen BA, Vietti T: Increased CSF folate with repeated folinic acid dosing. Br J Cancer 60:799, 1990 (letter)
53. Browman GP, Goodyear MDE, Levine MN, et al: Modulation of the antitumor effect of methotrexate by low dose leucovorin in squamous cell head and neck cancer: A randomized placebo controlled clinical trial. J Clin Oncol 8:203-208, 1990